Home → E-shop → Antiviral compounds → Molnupiravir – CAS 2349386-89-4

Molnupiravir – CAS 2349386-89-4

Molnupiravir – CAS 2349386-89-4 is provided by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

98%+

Package contents

Molnupiravir

This compound is for research use only. We do not sell to patients.

Amount

50 mg	€ 160	Stock
100 mg	€ 270	Stock
1 g	€ 600	Stock
Do you want custom amount?			Custom amount

Amount

50 mg

€ 160

Stock

100 mg

€ 270

Stock

View more amounts

Characterisation

CAS: 2349386-89-4

IUPAC name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate

Other names: EIDD 2801, Uridine-5′-methylpropanoate-4-oxime, Lagevrio, MK-4482, prodrug-EIDD-1931

Molecular weight: 329.31 g/mol

Molecular formula: C₁₃H₁₉N₃O₇

InChI: InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1

Description

Molnupiravir is used as a prodrug. It breaks down into a free ribonucleoside derivative inside the cell, and kinases convert the nucleoside into its relative 5‘-O-triphosphate, responsible for antiviral activity. The 5′-O-triphosphate (β-_D–N⁴-4-Hydroxycytidine 5′-triphosphate, EIDD-1931 5′-triphosphate or NHC-TP) is incorporated into the nascent viral RNA by RNA polymerase, causing mutations and the consequent extinction of the virus. This effect is generally called lethal mutagenesis. Molnupiravir can change its structure by tautomerism between a uridine-like form and a cytidine-like form and thus disguise itself from the virus, providing an advantage over other antiviral agents to which some viruses can develop resistance over time.

You can read more about Molnupiravir in our article.

Chemicals are distributed worldwide

Buy Molnupiravir now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Singh, A. K., Singh, A., Singh, R., & Misra, A. (2021). Molnupiravir in COVID-19: A systematic review of literature. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(6), 102329.
Caraco, Y., Crofoot, G. E., Moncada, P. A., Galustyan, A. N., Musungaie, D. B., Payne, B., … & De Anda, C. (2022). Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM evidence, 1(2), EVIDoa2100043.
Mahase, E. (2021). Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., … & De Anda, C. (2022). Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New England Journal of Medicine, 386(6), 509-520.